在亚临床动脉样硬化和高尿酸时表观遗传特征的改变
Maryam Beik-Khormizi1, Mohamad Reza Zare-Khormizi2,3, Ali Dehghani Firoozabadi4
1International Campus of Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Scientific reports
|July 2, 2025
概括
像DNMT3A和HDAC3/7这样的表观遗传因素与高尿酸 (UA) 和男性早期动脉样硬化有关. 这些表观遗传变化独立于传统的心血管风险因素而发生.
科学领域:
- 心血管表观遗传学 心血管表观遗传学
- 代谢综合征研究 代谢综合征研究
- 动脉样硬化病病因 病因学
背景情况:
- 尿酸 (UA) 和表观遗传修饰与心血管疾病 (CVD) 有关.
- 亚临床动脉样硬化症是心血管疾病的前体,需要对其潜在的分子机制进行调查.
- 了解UA,表观遗传学和早期动脉样硬化之间的相互作用对于风险分层至关重要.
研究的目的:
- 研究表观遗传因素,尿酸水平和亚临床动脉样硬化之间的关联.
- 为了比较高UA个体和那些因疑似冠状动脉疾病接受血管造影的人的基因表达特征,与正常的对照组进行比较.
主要方法:
- 对三组男性进行比较研究:早期冠状动脉血管学 (CPCA) 候选人,高UA (HUA) 和正常受试者 (NS),所有人都没有心血管风险因素 (CVRF).
- 在外周血液单核细胞 (PBMC) 中使用实时PCR分析DNMT3A/3B和HDAC3/7基因表达.
- 针对潜在混因素 (CVRF) 的统计调整.
主要成果:
- 与NS相比,CPCA和HUA组的DNMT3B和HDAC3/7表达显著较低 (p <0.05).与NS相比,CPCA和HUA组的DNMT3B和HDAC3/7表达显著较低.
- 在CPCA和HUA组中,DNMT3A表达显著更高 (p < 0.05),与UA水平负相关 (p ≈ 0.044).
- 表观遗传因素的变化与早期动脉样硬化和UA水平独立相关,无论常见的CVRFs.
结论:
- 表观遗传变化独立地与早期动脉样硬化和尿酸水平升高的存在有关.
- 超尿血和亚临床动脉样硬化与特定的表观遗传变化有关,即使没有传统的心血管风险因素.
- 这项研究突出了新的表观遗传点,以了解和潜在地管理心血管风险.
关键词:
冠状动脉疾病:冠状动脉疾病.DNMT: DNA 甲基转移酶.HDAC: 基斯脱乙酶 (Histone deacetylase) 是一种可以消毒基因的化合物.PBMC:周围血液单核细胞单核细胞.UA: 尿酸是指尿酸中的一种.更多相关视频
相关概念视频
Atherosclerosis I: Introduction
93
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
93
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
41
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
41
RNA Editing
9.2K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
222
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
222


